Testing effectiveness (Phase 2)Looking for participantsNCT05985655
What this trial is testing
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Who this might be right for
Head and Neck Squamous Cell Carcinoma (HNSCC)Pancreatic AdenocarcinomaNon-small Cell Lung Cancer (NSCLC)+3 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. 230